Over 580,000 bottles of a blood pressure medication have been recalled by the U.S. Food and Drug Administration (FDA) due to concerns over potentially harmful impurities. The recall affects Prazosin Hydrochloride capsules manufactured by Teva Pharmaceuticals, based in New Jersey. The FDA identified the presence of N-nitroso Prazosin impurity C, a substance classified as a carcinogen, in these products.
According to the FDA, the recall encompasses a total of **580,844 bottles** distributed across the United States. These capsules are available in doses of **1 mg, 2 mg, and 5 mg**. The recall was initiated on **October 7, 2023**, and was subsequently classified as a Class II recall on **October 24, 2023**. A Class II recall indicates that the product may cause temporary or medically reversible adverse health consequences.
Details of the Recall
The recall includes **55 lots** of Prazosin Hydrochloride capsules, with specific lot codes provided in the FDA notice. While no adverse effects have been reported so far, consumers are urged to verify if their medication is part of this recall. The FDA’s action aims to ensure public safety by addressing the potential health risks associated with the contaminated medication.
Teva Pharmaceuticals has communicated with affected customers, providing instructions for returning the recalled capsules. The company emphasized the importance of contacting pharmacies for guidance on how to handle any remaining medication. According to Teva, “Consumers with questions or concerns should also contact the health care provider who prescribed the medication.”
What to Do If You Are Affected
Individuals who possess Prazosin Hydrochloride capsules should review their medicine cabinets and check for the recalled products. It is advisable to discuss any concerns with healthcare providers to determine the best course of action. Those affected should follow the return instructions issued by Teva and ensure they are not using any potentially harmful medication.
In addition to this recall, consumers are encouraged to stay informed about other recent recalls. This includes a separate FDA recall impacting over **140,000 bottles** of another common statin, highlighting the importance of vigilance regarding medication safety.
As public health remains a priority, the FDA continues to monitor and address potential risks associated with pharmaceuticals, ensuring that consumers are protected from unsafe products.
